Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSHA-101 Gene Therapy for Infantile GM2 Gangliosidosis
NCT04798235Phase 2Active, not recruiting
- Start
- Mar 2021
- Primary completion
- Mar 2027
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of TSHA-101 in GM2 gangliosidosis. Started Mar 2021; status: active, not recruiting.
02
Drugs
TSHA-101
03
Conditions
GM2 gangliosidosis
Beyond the preview
Go deeper on NCT04798235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04798235.